Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT01831141 |
| Other study ID # |
CSKP |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
April 11, 2013 |
| Last updated |
April 11, 2013 |
| Start date |
June 2010 |
| Est. completion date |
June 2013 |
Study information
| Verified date |
April 2013 |
| Source |
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi |
| Contact |
Giovanni Montini, MD |
| Phone |
+390516364617 |
| Email |
giovanni.montini[@]aosp.bo.it |
| Is FDA regulated |
No |
| Health authority |
Italy: Ethics Committee |
| Study type |
Observational
|
Clinical Trial Summary
Congenital solitary kidney (CSK) is a disorder caused by an abnormal development of one of
the two kidneys. The reported incidence ranges between 1:450-3200. It is debated whether CSK
is a benign condition or not. A variable risk of developing proteinuria (11-27%),
hypertension (0-60%) and chronic kidney damage (3.5-30%) is described. This knowledge
derives mainly from retrospective studies performed in tertiary medical centers which is
difficult to compare for the following reasons: the number of individuals evaluated, the
length of follow-up and the outcome studied.
The aim of this longitudinal study is to assess, in a cohort of children with congenital
solitary kidney, during a 10 year follow-up period: 1) the rates of developing proteinuria,
hypertension and chronic kidney disease and the corresponding potential prognostic factors.
2) the role of new biomarkers of glomerular (Cystatin C) or tubular damage (NGAL, NAG,
B2-microglobulin) in predicting the appearance of chronic kidney damage.
Description:
Congenital Solitary kidney (CSK) is a disorder caused by the abnormal development of one of
the two kidneys. This abnormality can be either anatomical, caused by unilateral renal
agenesis (RAG), or functional, caused by extreme forms of dysplasia (renal aplasia-RAP and
multicystic dysplastic kidney disease-MCKD). The reported incidence is between 1:450-3200
with no difference between the two sexes. CSK is a subgroup of a large family of Congenital
Anomalies of the Kidney and Urinary Tract (CAKUT), which are caused by abnormal embryologic
development. Physiologically, the development of the kidney begins during the 3rd week of
gestation and proceeds through a series of phases: the pronephros, mesonephros, and
metanephros. While abnormalities of the early pronephros-mesonephros phases lead to renal
agenesis, an aberrant metanephros phase can cause a more wide spectrum of CAKUT. CAKUT are
the leading cause of chronic (50%) and end stage (40%) kidney disease in children. While
this risk is well known for some phenotypes (e.g. bilateral renal hypodysplasia and
posterior urethral valves), whether CSK is a benign condition or not, has been the subject
of recent debate. The knowledge of the natural history of CSK originates mainly from
retrospective studies often performed in tertiary medical centers which are difficult to
compare for several reasons: the number of individuals studied varied considerably as did
the underlying CSK disorders (RAG, MCKD or RAP), the length of follow-up and the type of
outcomes considered. These studies show an extremely variable risk of developing proteinuria
(11-27%), hypertension (0-60%), and chronic kidneys disease (3.5-30%). So there are many
difficulties which prevent us from understanding: a) which phenotype (RAG, MCKD or RAP) or
risk factors could influence the progression to an adverse outcome; b) whether or not the
compensatory hypertrophy and resulting hyperfiltration acts as a protective mechanism.
Recently, Sanna-Cherchi et al. retrospectively analyzed the long-term renal outcome of over
300 children with CAKUTs. With simple selection criteria, dialysis-free survival from birth
was modelled to account for concomitant vesicoureteral reflux, age at diagnosis,
hypertension, proteinuria, and serum creatinine concentration. Surprisingly the analysis
revealed that patients with solitary kidney have a probability of nearly 50 % of requiring
dialysis by 30 years of age. This clinical outcome raises the possibility that subclinical
defects could be present in the congenital solitary kidney which may account for a poorer
prognosis. This hypothesis is also supported by the fact that the long-term prognosis in
individuals with acquired single kidney (e.g. transplant donors or subject nephrectomized
for Wilm's tumor) appears to be excellent. This reported high risk of poor outcome in CSK
patients has highlighted the need for understanding: 1) the rate and the factors determining
progression to end-stage renal disease; 2) the development of biomarkers to improve early
detection. Usually, children with CSK are not always subjected to long term follow-up and
when they are, monitoring involves plasma creatinine concentration , proteinuria and
ultrasonography. Because most cases of endstage renal disease in children result from
tubulointerstitial rather than glomerular disorders, serum creatinine and urine protein
determinations are relatively insensitive. New biomarkers are now available that can
facilitate the early identification of changes in renal function before they become
irreversible. These biomarkers of glomerular (serum Cystatin C) or tubular damage (urine
alfa-1 and beta-2 microglobulin, urine lysozyme, serum and urine neutrophil gelatinase
associated lipocalin (NGAL), urine Na+/H+ exchanger (NHE3), urine Kidney injury molecule 1
(KIM1), urine N-acetyl-beta-D-glucosaminidase (NAG), already validated for various kidney
diseases (acute renal failure, nephrotic syndrome, etc), could be useful in the early
identification of damage in CSK patients.
The aim of this longitudinal study is to assess, in a cohort of children with CSK, during a
10-year follow-up period:
1. the rates of developing proteinuria, hypertension and chronic kidney disease and
potential prognostic factors.
2. the role of new biomarkers of glomerular or tubular damage in predicting the appearance
of chronic kidney damage.
Study population:
Study group: male and female children, aged 0-18 years, diagnosed with CSK, documented by
renal ultrasonography and confirmed by dimercaptosuccinic acid (DMSA) Scan. Written informed
consent will be obtained. Children with chronic renal failure, posterior urethral valves,
diabetes, heart and/or vascular diseases and autoimmune diseases will be excluded. Subjects
will be enrolled at the Paediatric Nephrology Department of the Sant'Orsola Malpighi
Hospital, Bologna, as in and/or outpatients from the 1st April 2010 to 30th April 2013; the
follow-up of each subject will continue for 10 years.
At the baseline all children will be assess by:
1. Medical history;
2. Physical examination (anthropometric and blood pressure measurements);
3. Kidney and urinary tract ultrasonography (US);
4. Voiding cystourethrography (VCUG);
5. Clinical laboratory assessments: complete blood count, serum electrolyte, serum
creatinine, serum urea, serum cystatin C, urine analysis, urine creatinine,
microalbuminuria, urine electrolyte, urine α1-microglobulin, urine β2-microglobulin,
urine lysozyme, serum and urine NGAL, urine NHE3, urine KIM1, urine NAG;
6. 99-technetium diethylene triamine pentaacetic acid scintigraphy (DTPA)(DTPA scan) in
children aged more than 2 years.
Patient follow-up and monitoring:
1. Clinical examination with height, weight, BMI, blood pressure every six months in
children up to 2 years and every year in children aged more than 3 years;
2. Biochemistry (every six months in children up to 2 years and every year in children
aged more than 3 years): complete blood count, serum electrolyte, serum creatinine,
serum urea, serum cystatin C, urine analysis, urine creatinine, microalbuminuria, urine
electrolyte, urine α1-microglobulin, urine β2-microglobulin, urine lysozyme, serum and
urine NGAL, urine NHE3, urine KIM1, urine NAG;
3. Kidney and urinary tract US with evaluation of renal length (every six months in
children up to 2 years and every year in children aged more than 3 years);
4. DTPA scan:
If age ≤ 2 years: at 2 , 5 and 10 ten years; If age > 2 years: at entry and then every five
years; 5. Ambulatory blood pressure measurement: If age ≤ 7 years: at 7 years, 10 years and
at the end of follow-up; If age > 7 years at entry and then every five years.
The following epidemiological, clinical and laboratory data will be collected:
Epidemiological data:
- Sex;
- Age at diagnosis;
- Ethnicity;
- History.
Clinical data:
- Height, weight and BMI at each visit,
- Blood pressure measurement at each visit.
Laboratory data:
• Complete blood count, serum electrolyte, serum creatinine, serum urea, serum cystatin C,
urine analysis, urine creatinine, microalbuminuria, urine electrolyte, urine
α1-microglobulin, urine β2-microglobulin, urine lysozyme, serum and urine NGAL, urine NHE3,
urine KIM1, urine NAG at each visit.
Instrumental data:
- US renal length at each visit;
- Glomerular filtration rate evaluated by DTPA scan;
- Ambulatory blood pressure meas
